Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $4.50.

TNYA has been the topic of several recent analyst reports. Chardan Capital reduced their price target on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, January 8th. HC Wainwright cut their price target on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Finally, Canaccord Genuity Group decreased their price objective on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, December 18th.

Institutional Trading of Tenaya Therapeutics

A number of large investors have recently modified their holdings of the company. Scientech Research LLC bought a new position in Tenaya Therapeutics in the third quarter worth approximately $27,000. Mirador Capital Partners LP lifted its holdings in shares of Tenaya Therapeutics by 38.2% in the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock worth $38,000 after buying an additional 6,500 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of Tenaya Therapeutics during the 3rd quarter worth $99,000. Persistent Asset Partners Ltd purchased a new position in shares of Tenaya Therapeutics during the third quarter valued at $117,000. Finally, Savant Capital LLC bought a new stake in shares of Tenaya Therapeutics in the second quarter valued at about $52,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Trading Up 5.3%

Shares of TNYA opened at $0.75 on Friday. The company’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.14. The company has a market cap of $125.53 million, a P/E ratio of -0.97 and a beta of 3.18. Tenaya Therapeutics has a twelve month low of $0.36 and a twelve month high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Analysts predict that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.